Patents Assigned to UCB Pharma S.A.
  • Fused thiazole derivatives as kinase inhibitors
    Patent number: 8710054
    Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: April 29, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Singh Aujla, Karen Viviane Lucile Crepy, Anne Marie Foley, Richard Jeremy Franklin
  • Antibody molecules having binding specificity for human IL-13
    Patent number: 8691233
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: April 8, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Antibodies specific to IL-17A and IL-17F
    Patent number: 8679494
    Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: March 25, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Thomas Allen Ceska, Alistair James Henry
  • LIPOCALIN 2 AS A BIOMARKER FOR IL-17 INHIBITOR THERAPY EFFICACY
    Publication number: 20140080134
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: ADAM SAMUEL PLATT, STEPHEN EDWARD RAPECKI, MARA FORTUNATO, DAVID ROBERT RAINEY, JON LEIGH RUNDLE, PAUL ALFRED SMITH, GILLIAN SAIRFULL WATT
  • ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F
    Publication number: 20140065674
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: RALPH ADAMS, TERENCE SEWARD BAKER, ALASTAIR DAVID GRIFFITHS LAWSON
  • Fused pyridine derivatives as kinase inhibitors
    Patent number: 8653272
    Abstract: A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 18, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Kerry Jenkins, Christopher James Lock, Andrew James Ratcliffe
  • Quinoline derivatives as kinase inhibitors
    Patent number: 8653105
    Abstract: A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: February 18, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F
    Publication number: 20140044732
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: September 24, 2013
    Publication date: February 13, 2014
    Applicant: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Co-crystals of pyrrolidinones
    Patent number: 8642641
    Abstract: The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R1 is a C-1-C6 alkyl group. R2 is a C-1-C6 alkyl group which is optionally substituted by 1 to 3 halogens or R2 is a C2-C6 alkenyl group.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: February 4, 2014
    Assignee: UCB Pharma, S.A.
    Inventor: Luc Quere
  • TREATMENT FOR BONE DISEASES
    Publication number: 20140030268
    Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 30, 2014
    Applicant: UCB PHARMA S.A.
    Inventor: Martyn Kim Robinson
  • Sclerostin binding antibody
    Patent number: 8637643
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: John Latham, David G. Winkler
  • Quinoline derivatives as kinase inhibitors
    Patent number: 8637543
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Thieno-pyridine derivatives as MEK inhibitors
    Patent number: 8637491
    Abstract: A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Thorne
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-6
    Publication number: 20140024077
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: June 27, 2013
    Publication date: January 23, 2014
    Applicant: UCB Pharma S.A.
    Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
  • Pharmaceutical composition of piperazine derivatives
    Patent number: 8633194
    Abstract: The present invention relates to a liquid composition containing an active substance belonging to the family of substituted benzhydryl piperazines with reduced amounts of preservatives.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: January 21, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Domenico Fanara, Jean Scouvart, Claire Poulain, Michel Deleers
  • Dual specificity antibody fusions
    Patent number: 8629246
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, the fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: January 14, 2014
    Assignee: UCB Pharma S.A.
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Substituted aniline derivatives
    Patent number: 8624022
    Abstract: The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: January 7, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Andrew David Carr, Judi Charlotte Neuss, Michael Glen Orchard, David William Porter
  • Nucleic acids encoding antibody molecules which bind IL-17A and IL-17F
    Patent number: 8617847
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: December 31, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Antibody molecules having specificity for human OX40
    Patent number: 8614295
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: December 24, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20130330344
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 12, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW MALCOLM NESBITT, ANDREW GEORGE POPPLEWELL, STEVAN GRAHAM SHAW, DIANA SHPEKTOR, YI ZHANG